ABL1 and acute lymphoblastic leukemia: As described in the literature, the overall rates and prognosis of ALL patients with BCR-ABL (Ph+) are very poor32,33, and aurora kinase inhibitors provided a new option for future clinical and therapeutic options for these individuals34.